Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale.

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has ...

Merck will buy Minneapolis-based Bio-Techne Corp. in a deal worth $11.3 billion. Bio-Techne was under pressure from an ...

After a difficult period in FY22, Bio-Techne has endured a similar fate into the new year. Our previous tactical speculative buy call hasn't played out in the name; unfortunate, but the reality. Here ...

Gemini Bioproducts announced the acquisition of selected fetal bovine serum product rights and inventory from Bio-Techne (TECH). GeminiBio has a 39-year history of supporting FBS customers. With this ...

Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth ...